PA-9|cas:1436004-46-4|西域试剂

PA-9,99.60%

产品编号：Bellancom-129421| CAS NO：1436004-46-4| 分子式：C₁₇H₁₈N₆O₂| 分子量：338.36

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-129421	￥2000.00	杭州北京（现货）
Bellancom-129421	￥5800.00	杭州北京（现货）
Bellancom-129421	￥11500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PA-9

产品介绍

PA-9 是一种垂体腺苷酸环化酶激活多肽 (PACAP) I 型 (PAC1) 受体拮抗剂。PA-9 剂量依赖性地抑制 PACAP 诱导的 cAMP 升高，IC₅₀ 为 5.6 nM。PA-9 可用于研究神经性和/或炎症性疼痛。

生物活性

PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC₅₀ of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain.

体外研究

PA-9 (10 pM to 10 nM; 30 minutes) dose dependently inhibits PACAP-induced (1 nM) CREB phosphorylation in the CHO cells expressing PAC1 receptors.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

PA-9 (100 pmol; co-injection with PACAP) attenuates the development of PACAP-induced (100 pmol/5 μL; intrathecal injection) aversive responses of mice.
PA-9 (100 pmol; co-injection with PACAP) significantly blocks the induction of PACAP-induced (100 pmol) mechanical allodynia.
PA-9 (100 pmol/5 μl; single intrathecal injection alone) does not induce aversive responses and mechanical allodynia of mice.
PA-9 is well accommodated in the subpocket formed by L80, F81, I83, G91, V92, P107, A112, and C113 of the PAC1 receptor, precipitating in hydrophobic interactions.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ddY mice (6 weeks old at the start of experiments; intrathecal injection 100 pmol/5 μL PACAP)
Dosage:	intrathecal injection, co-injection with PACAP.
Administration:	100 pmol/5 μL
Result:	Attenuated the development of PACAP-induced aversive responses. Blocked the induction of PACAP-induced mechanical allodynia.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ddY mice (6 weeks old at the start of experiments; intrathecal injection 100 pmol/5 μL PACAP)
Dosage:	intrathecal injection, co-injection with PACAP.
Administration:	100 pmol/5 μL
Result:	Attenuated the development of PACAP-induced aversive responses. Blocked the induction of PACAP-induced mechanical allodynia.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (738.86 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.9554 mL	14.7772 mL	29.5543 mL
5 mM	0.5911 mL	2.9554 mL	5.9109 mL
10 mM	0.2955 mL	1.4777 mL	2.9554 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式